The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

As per The Business Research Company’s Immuno-Oncology Drugs Global Market Report 2023, The global immuno-oncology drugs market is expected to grow from $70.59 billion in 2022 to $81.46 billion in 2023 at a compound annual growth rate (CAGR) of 15.4%. The market size of global immuno-oncology drugs is expected to grow from $136.15 billion in 2027 at a CAGR of 13.7%.

What was the major driver in the immuno-oncology drugs market?
Increasing global cancer cases drive the immuno-oncology drugs market. In January 2022, American Cancer Society projected 1.9 million new cancer diagnoses and 609,360 deaths in the US, about 1,670 daily. Lung, prostate, bowel, and breast cancers comprise 43% of new cases worldwide. Rising global cancer rates expected to bolster immuno-oncology drug demand.

View More On The Immuno-Oncology Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

What was the key trend in the immuno-oncology drugs market?
Companies in the immuno-oncology drugs market boost innovation via strategic collaborations. To thrive in this competitive field, firms create inventive products and share expertise. For example, AbbVie collaborated with I-Mab Biopharma in September 2020 to develop Lemzoparlimab, an anti-CD47 monoclonal antibody for cancer treatment. The agreement encompasses development and commercialization, with potential for future collaborations.

Which was the largest region in the immuno-oncology drugs market?
North America was the largest region in the immuno-oncology drugs market in 2022. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Who are the immuno-oncology drugs market prominent players?
Major players in the immuno-oncology drugs market are Amgen Inc., AstraZeneca PLC., Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, and AbbVie Inc.

Key immuno-oncology drugs market segments
The global immuno-oncology drugs market is segmented –
1) By Type: Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Other Types
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Other Therapeutic Applications
3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes

Request A Sample Of The Global Immuno-Oncology Drugs Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

The Immuno-Oncology Drugs Global Market Report 2023  provides a comprehensive overview on the immuno-oncology drugs market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Oncology Molecular Diagnostics Global Market Report 2023
Oncology Devices Global Market Report 2023
Drugs For Immunotherapy Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model